- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
Pharmacological Management of Parkinson’s Disease
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor symptoms, including tremors, bradykinesia, and muscular rigidity. Given the alarming increase in the burden of PD, timely and effective treatment strategies are important for managing patients with the disease. In the Annual Scientific Meeting of the Hong Kong Movement Disorder Society, Professor Susan Fox of the University of Toronto reviewed the pharmacological therapies for PD patients, and the early PD with levodopa-induced fluctuation. Prof. Fox also shared her experience on PD management during a pandemic.
WATCH NOW
Susan H. FOXCanada -
RECORDED
Current Trends in the Diagnosis and Management of Parkinson’s Disease
The advances in understanding the neurobiology of Parkinson’s Disease (PD) have led to advances both in the diagnosis and therapeutic management of this neurodegenerative disease. Other than L-Dopa, multiple refinements of pharmacological approach have increased the degree of benefit, which includes enzyme inhibitors of MAO-B and COMT, dopamine agonists as well as non-dopaminergic agents. Infusion therapies and DBS offer relief to L-Dopa related motor complications. In the 35th Annual Scientific Meeting of the Hong Kong Neurological Society, Prof. Werner Poewe of the Medical University of Innsbruck Austria offered a lecture on current updates in diagnosing and managing PD.
WATCH NOW
Werner POEWEAustria -
RECORDED
Scientific Webinar - Medical Comorbidities of Psychiatric Patients
This webinar will discuss the inter-relationship between obesity, diabetes and various psychiatric diseases and its management. Dr. Chan will also address the common side effects of various psychiatric medications and the common drug-drug interactions between antidepressants and other medications.
WATCH NOW
Chan Hoi Chung SamuelHong Kong -
RECORDED
Scientific Webinar - The Importance of Early Optimized Treatment to Early Recovery of Daily Functioning
In this webinar, we will focus on achieving full functional recovery in patients with MDD including the improvement in cognitive, social and work functioning with case demonstration. The common symptoms of MDD, such as emotional blunting and anhedonia, and their implications for functional recovery will be analyzed. Dr. Wong will also share his expert opinion in the importance of individualized treatment in relation to the patients with various symptom profiles. The treatment options and holistic management of the patients with MDD will be reviewed in the lecture.
WATCH NOW
Wong Ming Cheuk MichaelHong Kong -
RECORDED
Scientific Webinar - What to Consider When Treating Patients with Anhedonia, Emotional Blunting and Low Motivation
The common and persistent symptoms of MDD including anhedonia, emotional blunting and low motivation will be explored in this webinar. Dr. Tsang will address the assessment and treatment methods for managing these 3 common symptoms for MDD patients in achieving full functional recovery. The latest scientific data and case sharing will also be featured in this lecture.
WATCH NOW
Tsang Fan KwongHong Kong -
RECORDED
Joint Scientific Webinar - Recent Advances in The Management of Disorder of Gut-Brain Interaction – Part I
Disorders of Gut-Brain Interactions (DGBI) has been increasingly used to replace Functional Gastrointestinal Disorders (FGID) in recent years. The new terminology highlights the role of dysfunctional brain-gut axis in the pathophysiology of FGID. It is well known that most DGBI patients do not respond well to gut-directed therapy alone. An effective management approach of DGBI needs to be multi-targeted, which starts with evaluation of multidimensional clinical profile during diagnosis, stressor identification, lifestyle and dietary modification, and medical therapy. Owing to the high prevalence and strong association with psychiatric comorbidity, vigilance should be exercised to facilitate early intervention by mental health professionals. In recent years, gut microbial modulation through probiotics and functional food has been investigated for treatment of DGBI with promising results.
WATCH NOW
Wu Che Yuen JustinHong Kong -
RECORDED
Joint Scientific Webinar - Recent Advances in The Management of Disorder of Gut-Brain Interaction – Part II
Complex gut disorders may have psychiatric etiology. Proper use of psychotropics is important under such circumstances. There are many psychotropics available nowadays. This lecture will present principles and guidelines for choosing the appropriate ones for the patients.
WATCH NOW
Siu Wa TangHong Kong -
RECORDED
Scientific Webinar - Recent Advances in The Management of Major Depressive Disorder
This webinar will include a review of the advances in the management of MDD, with reference to the latest Canadian Network for Mood and Anxiety treatment clinical guidelines. Dr. Yip will also share three cases related to the use of antidepressants and the use of augmentation medications.
WATCH NOW
Yip Pui LamHong Kong -
RECORDED
Scientific Webinar - Use of Antidepressants in Primary Care Clinic
In this webinar, Dr Law will share the experience of treating mood disorder in GP setting as well as experience in using vortioxetine. Case sharing and discuss how to start treating mood disorder in general practice.
WATCH NOW
Law Sai OnHong Kong -
RECORDED
Joint Scientific Webinar Crosstalk Between The GI Tract and The Brain
Functional gastrointestinal disorders, also known as disorders of gut-brain interaction, is common among the adult population in Hong Kong. In this joint symposium, Prof. Justin Wu gives an overview on the bidirectional interaction between brain and gut, etiology, and treatment for these disorders. Prof. Tang Siu Wa discusses the role of inflammation in neuropsychiatric disorders with a perspective from traditional Chinese medicine.
WATCH NOW
Wu Che YuenHong Kong
Tang Siu WaHong Kong -
RECORDED
Highlights of 2021 MDS Congress & Case Discussions on Parkinson's Disease
Our 3 speakers will be discussing on some key topics of MDS Virtual Congress 2021 in this webinar, these includes telemedicine clinic for Parkinson’s Disease, health disparities in Parkinson’s Disease and key updates on recent trials in Parkinson’s Disease. Our speakers will also attempt to share some best practices in the management of Parkinson's Disease through case sharing presentations in different stages of Parkinson's Disease.
WATCH NOW
Roongroj BhidayasiriThailand/Chair & Speaker
Roland Dominic G. JamoraPhilippines/Speaker
Olivier RascolFrance/Speaker -
RECORDED
Alzheimer's disease in 2021 & beyond
Our two expert speakers – Dr Alireza Atri and Professor Miia Kivipelto – will take us through a brief history of Alzheimer’s disease to the modern-day view. In his Chair’s introduction, Dr Atri will briefly review 100 years of Alzheimer’s disease and research. Professor Kivipelto will then explore the challenges and consequences that the COVID-19 pandemic has brought to the care of patients with dementia. She will also consider future challenges, reviewing the epidemiology of Alzheimer’s disease, risk factors, and prevention strategies. Dr Atri will follow on with a contemporary view of treatment goals and will discuss aspects of multifactorial care.
WATCH NOW
Alireza AtriUSA
Miia KivipeltoSweden -
RECORDED
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDEDMasterclass Webinar series
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
Treatment Challenges in Managing GAD
In this webinar, Dr Blier & Dr Cutler will be discussing the differences between normal anxiety & generalized anxiety disorder (GAD), the pharmacology treatments in GAD & also the challenges in managing GAD. Both experts will be sharing evidence based data and also their personal clinical experiences in this virtual event.
WATCH NOW
Pierre BlierCanada
Andrew J. CutlerUnited States
- All
- Neurology
- Psychiatry
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
Patient profiles that we should NOT prescribe vortioxetine
Have you ever wondered if there is any specific patient profile that you should avoid giving vortioxetine? In this webinar, there will be a debate session between these speakers on whether vortioxetine should or should not be prescribed in different patient profiles. Speakers will also be sharing their own local clinical experiences in MDD; We expect the 60 minutes webinar to be interactive & fun, see you virtually.
WATCH NOW
Pratap ChokkaCanada
Bernhard BauneGermany
Stavroula BargiotaGreece -
RECORDED
Optimizing Functional Recovery in Schizophrenia Symposium
The treatment goal in treating schizophrenia has changed substantially from expecting a modest control of psychotic symptoms to considering functional recovery as an ultimate goal. In this virtual symposium, a group of experts will be discussing on: • Treatment priorities in schizophrenia care • Impact of relapses prevention in schizophrenia • How to achieve functional recovery in schizophrenia • How to better engage with patients to encourage behavioral change • The role of monthly treatment in schizophrenia
WATCH NOW
Ahmad Hatim SulaimanMalaysia
Salina Abdul AzizMalaysia
Philip GorwoodFrance
Michael Ang | Nik Ruzyanei Nik JaafarMalaysia | Malaysia -
RECORDED
Alzheimer's disease in 2021 & beyond
Our two expert speakers – Dr Alireza Atri and Professor Miia Kivipelto – will take us through a brief history of Alzheimer’s disease to the modern-day view. In his Chair’s introduction, Dr Atri will briefly review 100 years of Alzheimer’s disease and research. Professor Kivipelto will then explore the challenges and consequences that the COVID-19 pandemic has brought to the care of patients with dementia. She will also consider future challenges, reviewing the epidemiology of Alzheimer’s disease, risk factors, and prevention strategies. Dr Atri will follow on with a contemporary view of treatment goals and will discuss aspects of multifactorial care.
WATCH NOW
Alireza AtriUSA
Miia KivipeltoSweden -
RECORDED
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
Towards a paradigm shift in treatment of bipolar disorder
Bipolar Disorder Is an episodeic, lifelong illness with a variable course. The high recurrent nature of the disease can be very difficult to manage. Poor adherence to treatment is a significant problem to the management of the disease thus resulting in suboptimal outcome. In conjunction with World Bipolar Dat, Prof Eduard Vieta will be sharing the role of long-acting injectable antipsychotic in the management of bipolar disorder alongside with Prof Ahmad Hatim, sharing his clinical experience. This webinar aims to address the unmet needs in the treatment of bipolar disorder.
WATCH NOW
Michael AngMalaysia
Eduard VietaSpain
Ahmad Hatim SulaimanMalaysia -
RECORDED
Treatment duration in Bipolar Disorder & Schizophrenia
Schizophrenia and bipolar disorder are both mental illnesses that are commonly associated with impairments in social and occupational functioning. Long-term effective treatments that can reduce the relapse rate in these diseases is one of the keys to treatment success. In this webinar, it addresses the need for long-term continuous treatment and the role of long-acting injectables in both schizophrenia and bipolar disorder.There is also an interactive discussion on the topic during the Q&A session
WATCH NOW
Amer SiddiqMalaysia
Andrea FagioliniItaly -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder
Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.
WATCH NOW
Roger S. McIntyreCanada
Gregory MattinglyUnited States -
RECORDED
Masterclass Webinar Series - Anhedonia and Emotional Blunting in Major Depressive Disorder - Addressing Challenges in clinical management of MDD
Anhedonia is an integral clinical feature of MDD (major depressive disorder) which is often neglected in clinical practice, defined by the lack of pleasure and motivation. Treatment with antidepressants could cause emotional blunting in some patients, which phenotypically overlaps with anhedonia. In this webinar, the challenges in clinical management of anhedonia and emotional blunting will be addressed, as well as the clinical approach and choice of optimal treatment options.
WATCH NOW
Roger S. McIntyreCanada
Andrea FagioliniItaly -
RECORDED
THINK Depression Part 1: Connecting with your patients living with depression
Interested to find out what are the challenges faced by general practitioner when it comes to treating depression? This session will discuss on how to disclose depression to your patients, recommended bedside manners, setting the foundation & putting it into practice. The changing landscape of treatment goal will also be discussed. The speakers will also discuss on communication being the key to understand patients experience & functional recovery being the aim in the treatment of depression.
WATCH NOW
Beatrice Ng AndrewMalaysia
Yee Kok WahMalaysia -
RECORDED
THINK Depression Part 2: Understanding co-morbid depression & anxiety
This session will discuss the hurdles in managing anxiety. How do we differentiate depression and anxiety? What are the symptoms, assessment tools and treatment choices available? We will also be discussing the role of the general practitioner in treating depression and co-morbid anxiety.
WATCH NOW
Prof Philip GeorgeMalaysia -
RECORDED
THINK Depression Part 3: Battling Depression - The road to functional recovery
Depression is a heterogeneous disease. It is more than just low mood, it also affects your body and the way you think. What will be the treatment goal when it comes to treating depression? What will be our role as front-liners during such a pandemic to battle depression?
WATCH NOW
Beatrice Ng AndrewMalaysia
Michael AngMalaysia -
RECORDED
Explore the new possibilities - Part 1 Schizophrenia
Schizophrenia is a progressively debilitating mental disorder comprising positive, negative and cognitive symptoms. The course and outcome of schizophrenia can be very different and shaped by accurate diagnosis and well-chosen medications. Presently, multiple agents are available for the treatment of schizophrenia; however, the majority do not address negative and cognitive symptoms. Thus, it remains as one of the unmet needs in the treatment of schizophrenia. Introducing the new treatment option for schizophrenia to address not only positive symptoms but also negative and cognitive symptoms to help patients to be functioning and integrate back to society again.
WATCH NOW
Gregory MattinglyUnited States -
RECORDED
Explore the new possibilities - Part 2 Adjunctive Therapy in MDD
Major depressive disorder (MDD) is a multifaceted condition with emotional, cognitive and physical symptoms that affect psychosocial functioning and quality of life. The best treatment outcome for a patient with MDD is a return to an optimal level of functioning, which may include the ability to maintain a job, build and retain relationships and interact with others. However, despite the availabiliity of different classes of antidepressants, many patients with MDD still experience an inadequate response to antidepressants, prolonging loss of social functioning and sense of well-being. Therefore, the role of an adjunctive therapy in MDD is needed to help patients achieve their full recovery and return to their functioning again.
WATCH NOW
Gregory MattinglyUnited States
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
LIVE
Treatment of Depression comorbid with Neurological Disease
05th November 2022, 1300 to 1400 (Pakistan time)
In this webinar experts will highlight the treatment of Depression with comorbid Neurological Diseases and critical factor to select antidepressants for patients with neurological diseases.
REGISTER NOW
Dr. Anil Kumar WadhwaniPakistan -
RECORDED
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
Treatment Challenges in Managing GAD
In this webinar, Dr Blier & Dr Cutler will be discussing the differences between normal anxiety & generalized anxiety disorder (GAD), the pharmacology treatments in GAD & also the challenges in managing GAD. Both experts will be sharing evidence based data and also their personal clinical experiences in this virtual event.
WATCH NOW
Pierre BlierCanada
Andrew J. CutlerUnited States
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
The Implications of Depression in GAD and Post-stroke Patients
Often associated with symptoms overlap, Generalized Anxiety Disorder (GAD) with Major Depressive Disorder (MDD) is one of the most common anxiety-mood comorbidity types. With the continuous rise of pandemic-related mental health issues, proper management of both disorders is imperative. The first topic will discuss the challenges associated with the diagnosis and treatment of patients with both GAD and MDD, done through a case presentation to further relate it to one’s overall well-being. Going further into the implications of depression in the patient's quality of life, the second session focuses on Post-Stroke Depression (PSD) as it is often associated with poorer functional outcomes and increased risk of mortality. This presentation highlights the prevalence and impact of this comorbidity, with the objective to develop an approach for the assessment and management of Post-Stroke Depressed patients.
WATCH NOW
Jannel Gatlabayan-CletoPhilippines
Gerardo SalazarPhilippines -
RECORDED
Zooming In: The Impact of COVID-19 Quarantine in Managing BPSD
With the year-long quarantine still in place, the more common behavioral and psychological symptoms of dementia (such as irritability, apathy or agitation) may either worsen or start to manifest, negatively affecting the quality of life of both the patient and the caregiver. In this webinar, the management of these symptoms in the midst of these restrictions will be discussed through patient case presentations, with a zoom in on depression in patients with Alzheimer's Disease.
WATCH NOW
Encarnita Raya-AmpilPhilippines
Pia Natalya Reyes-SiaPhilippines -
RECORDED
Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder
Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.
WATCH NOW
Roger S. McIntyreCanada
Gregory MattinglyUnited States -
RECORDED
Masterclass Webinar Series - Anhedonia and Emotional Blunting in Major Depressive Disorder - Addressing Challenges in clinical management of MDD
Anhedonia is an integral clinical feature of MDD (major depressive disorder) which is often neglected in clinical practice, defined by the lack of pleasure and motivation. Treatment with antidepressants could cause emotional blunting in some patients, which phenotypically overlaps with anhedonia. In this webinar, the challenges in clinical management of anhedonia and emotional blunting will be addressed, as well as the clinical approach and choice of optimal treatment options.
WATCH NOW
Roger S. McIntyreCanada
Andrea FagioliniItaly -
RECORDED
Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?
The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.
WATCH NOW
Andrea FagioliniItaly
Andrew J. CutlerUnited States -
RECORDED
Masterclass Webinar Series - Addressing functional challenges for patients with MDD
The definition of treatment success in MDD (major depressive disorder) has evolved across the years to full functional recovery, where the patient returns back to a premorbid level of functioning. This requires the complete treatment of mood, cognitive and physical symptoms of MDD, and the choice of antidepressant is integral to full recovery. In this webinar, the speakers will address the challenges to achieving functional recovery for MDD patients, and present clinical evidence for vortioxetine as a treatment option, as well as share their practical experience.
WATCH NOW
Pratap ChokkaCanada
Iria GrandeSpain -
RECORDED
MDD and Anxiety: Meeting mental health challenges in this pandemic
The pandemic has further increased depression and anxiety cases worldwide. With October as the World Mental Health Month and with this year’s global theme as “Mental Health for All”, concrete steps are needed in order to address the new challenges presented by COVID-19. Pharmacological treatment is one of these options. The role of resilience in MDD and managing pandemic-triggered anxiety will be the main discussion points in this webinar. Case presentations will also be used to highlight their implications in actual clinical practice.
WATCH NOW
Monina Garduño-CruzPhilippines
Roger S. McIntyreCanada -
RECORDED
The Psychiatric Emergency: Managing Agitated Patients
Agitation is one of the most common psychiatric emergencies seen in patients suffering from mental illnesses. The anxiety and isolation caused by the pandemic may also trigger this behavior. This webinar will focus on the different approaches in effectively managing agitated patients based on behavior severity. Relevant clinical guidelines on the topic will also be discussed.
WATCH NOW
Fareda Fatima FloresPhilippines
Myra Dee Lopex-RocesPhilippines -
RECORDED
How Telemedicine and Antidepressants Improve the Management of Neurological Disorders
Management of Parkinson's Disease may be challenging given the pandemic, limiting fact-to-face interactions between doctors and patients, telemedicine has come to the forefront in managing the disease. It will tackle how teleconsultations can affect clinical outcomes and patient's overall satisfaction. Several factors should be considered in choosing antidepressant for a patient and it needs to be individualized according to the patient's concomitant medication, metabolic profile, co-existing medical conditions, and the likelihood of drug-drug interactions.
WATCH NOW
Arlene NgPhilippines
Prof. Siu wa TangHong Kong
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
Scientific Discussion: A new Oral Drops, Solution in Major Depressive Disorder
· 1 CME Point Singapore Medical Association SMC20230207-1B-0021The new Vortioxetine oral drops solution is the first antidepressant drops solution available in Singapore. In this webinar, Dr Seng Kok Han will be sharing on the topic "Do we need this solution?", highlighting the usefulness and place in therapy of liquid formulations of psychotropics. Associate Professor Giovanni Martinotti will be discussing "Good reasons to use oral drops: From adverse events to opportunities for modulating treatment," covering the safety, efficacy and practical considerations for Vortioxetine oral drops solutions use in clinical practice. Associate Professor Giovanni will also be sharing his experiences with the Vortioxetine oral drops solutions in Italy.
WATCH NOW
Dr Seng Kok HanSingapore
Associate Professor Giovanni MartinottiItaly
Professor Roger HoSingapore -
RECORDED
A new loading dose strategy for Aripiprazole Once Monthly Injection – Two Injection Start (TIS)
· 1 CME Point Singapore Psychiatric Association SMC Event ID: SMC20220826-1B-0050Long-acting injectable (LAI) formulations of atypical antipsychotics are valuable treatment alternatives to oral agents and provide the opportunity to achieve sustained plasma therapeutic concentrations in the therapeutic range and, consequently, improvement in long-term outcomes. In this webinar, Dr Murat Yildirim, would be sharing more insights with the newly approved loading dose regime for Aripiprazole Once Monthly (AOM) Intramuscular Injection. We are also honoured to have Prof Christoph U. Correll to be sharing his clinical experience with this new loading dose regime since its regulatory approval. 1. Perlis R et al 2003. Evidence-based strategies for achieving treatment goals in bipolar disorder: A review and synthesis of contemporary treatment guidelines. Current Psychosis & Therapeutics Reports 1, 85–92 (2003)
WATCH NOW
Dr. Murat YildirimDenmark
Professor Christoph U. CorrellUSA
Dr Amelia SimSingapore -
RECORDED
Beyond symptoms control, what’s next for a bipolar patient?
The fundamental goals of treatment in bipolar disorder are full remission of acute mood episodes and prevention of future episodes1. Beyond symptoms control, what can else can we achieve together with a bipolar patient? In this webinar, Prof Tohen will share with us aspects of continuous improvement in functioning in bipolar patients, particularly with the use of long acting injectable antipsychotics. Dr Mok will also share a local case experience on a patient on aripiprazole once monthly injection. 1. Perlis R et al 2003. Evidence-based strategies for achieving treatment goals in bipolar disorder: A review and synthesis of contemporary treatment guidelines. Current Psychosis & Therapeutics Reports 1, 85–92 (2003)
WATCH NOW
Prof Mauricio TohenUSA
Dr Mok Yee MingSingapore -
RECORDED
Restoring functioning in depression, what does it mean?
· 1 CME point, Singapore Psychiatry Association, SMC Event ID: SMC20220428-1B-0006Despite being the mainstay of pharmacological treatment for Major Depressive Disorder (MDD), more than half of patients do not respond to antidepressant treatment (ADT), as shown by the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.¬¹ As a consequence of depressive symptoms, patients with MDD typically have impaired functioning across multiple domains, including work, social, and family functioning. ² ⁻ ³ What strategies could then be helpful for MDD patients to get back to where they desire?¬ This webinar discusses the role of adjunctive Brexpiprazole in MDD and its role beyond improvement of depressive symptoms.¬ Join us as our speakers share some newer data with Brexpiprazole as well as identifying suitable patient profiles for adjunctive treatment through case discussions.¬
WATCH NOW
Prof Michael E. ThaseUSA
David Teo Choon LiangSingapore
Marcus TanSingapore -
RECORDED
Differentiating brexpiprazole from the other antipsychotics – Focus on Major Depressive Disorder
According to the STAR*D study, around 50% of patients with MDD do not have an adequate response to their first antidepressant1. Inadequate responders to antidepressant treatment often feel frustrated, hopeless and anxious when their treatment is not helping their mental health2. In this webinar, Prof Leslie Citrome, USA will be sharing medication strategies to address non-response or inadequate response in MDD. Prof Citrome will also be sharing a comparison of published evidence on adjunct treatments in MDD and his clinical experience. In addition, Prof Amer Siddiq, Malaysia will be sharing his clinical experience in managing difficult-to-treat MDD patients. This session will be chaired by Dr Seng Kok Han, Singapore. *MDD - Major Depressive Disorder References – 1. Rush AJ, et al. Am J Psychiatry. 2006;163(11):1905-1917. 2. Mago et al. BMC Psychiatry 2018;18(1):33;
WATCH NOW
Seng Kok HanSingapore
Leslie CitromeUSA
Amer SiddiqMalaysia -
RECORDED
Tailoring Treatment for Depression: A focus on patients with Anhedonia or Emotional Blunting
In this session, the discussion will be focusing on the differences and similarities between anhedonia and emotional blunting, their impact on patients’ lives and how to identify them in clinical practice. New data will be shared on the effects of vortioxetine on anhedonia as well as from the COMPLETE study which focused on emotional blunting. The clinical implications of these studies and real-world observations will also be discussed.
WATCH NOW
Andrea FagioliniItaly -
RECORDED
Measure Outcome, Redefine Expectation in MDD
Patient vocabulary can sometimes include terms like a lack of “feeling like themselves again” or “being able to actually be around people for the first time. Prof Roueen Rafeyan is a practicing psychiatrist in Chicago, Illinois where he is Board certified in Psychiatry, Neurology and Addiction medicine, and was chosen as one of the Top Psychiatrist in the Nation by consumer Report 2007. He was one of the youngest psychiatrists to be given the Distinguished Fellow designation by American Psychiatric Association 2010. In this talk, Prof Rafeyan will speak on Measure Outcomes, and Redefine Expectations for patients to get MORE out of life.
WATCH NOW
Prof Roueen RafeyanUnited States -
RECORDEDMasterclass Webinar series
COVID-19 & MDD: Current challenges and implications for clinical practice
In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
WATCH NOW
Roger S. McIntyreCanada
Mohammad AlsuwaidanKuwait
Nina SchweinfurthSwitzerland -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
Aripiprazole LAI on the treatment of early phases schizophrenia
Treatment adherence is one of the key challenges in the management in schizophrenia. This webinar aims to share two case studies from Taiwan and Turkey on the role of monthly treatment in the early phases of schizophrenia.; we are also expecting to have an interactive Q&A session to discuss the practicality on pharmacology treatment in schizophrenia.
COMING SOON
Paul LeePhilippines
Chiu Nan YingTaiwan
Neslihan Akkisi KumsarTurkey -
RECORDED
Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder
Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.
WATCH NOW
Roger S. McIntyreCanada
Gregory MattinglyUnited States -
RECORDED
Masterclass Webinar Series - Anhedonia and Emotional Blunting in Major Depressive Disorder - Addressing Challenges in clinical management of MDD
Anhedonia is an integral clinical feature of MDD (major depressive disorder) which is often neglected in clinical practice, defined by the lack of pleasure and motivation. Treatment with antidepressants could cause emotional blunting in some patients, which phenotypically overlaps with anhedonia. In this webinar, the challenges in clinical management of anhedonia and emotional blunting will be addressed, as well as the clinical approach and choice of optimal treatment options.
WATCH NOW
Roger S. McIntyreCanada
Andrea FagioliniItaly -
RECORDED
Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?
The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.
WATCH NOW
Andrea FagioliniItaly
Andrew J. CutlerUnited States -
RECORDED
Masterclass Webinar Series - Addressing functional challenges for patients with MDD
The definition of treatment success in MDD (major depressive disorder) has evolved across the years to full functional recovery, where the patient returns back to a premorbid level of functioning. This requires the complete treatment of mood, cognitive and physical symptoms of MDD, and the choice of antidepressant is integral to full recovery. In this webinar, the speakers will address the challenges to achieving functional recovery for MDD patients, and present clinical evidence for vortioxetine as a treatment option, as well as share their practical experience.
WATCH NOW
Pratap ChokkaCanada
Iria GrandeSpain -
RECORDED
Treatment Challenges in Managing GAD
In this webinar, Dr Blier & Dr Cutler will be discussing the differences between normal anxiety & generalized anxiety disorder (GAD), the pharmacology treatments in GAD & also the challenges in managing GAD. Both experts will be sharing evidence based data and also their personal clinical experiences in this virtual event.
WATCH NOW
Pierre BlierCanada
Andrew J. CutlerUnited States -
RECORDED
Insights into current therapeutic management strategies in Parkinson’s Disease
This scientific video seeks to review current diagnosis and treatment goals of Parkinson’s disease. The objective is to enhance and update the knowledge in management of Parkinson's disease - newer and wider utilization of therapeutic strategies will improve patient outcomes and pharmacological management of conditions that incorporates patients’ specific needs, experiences, and the professionals’ clinical judgement. The speaker will share the latest evidence-based medicine review of therapies to control symptom, improve quality of life, prevent disease progress, etc. Case studies will be used to discourse how to choose different options for effective management of different stages along the Parkinson’s disease trajectory
WATCH NOW
Prof Susan H FoxCanada
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder
Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.
WATCH NOW
Roger S. McIntyreCanada
Gregory MattinglyUnited States -
RECORDED
Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?
The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.
WATCH NOW
Andrea FagioliniItaly
Andrew J. CutlerUnited States -
RECORDED
Treatment Challenges in Managing GAD
In this webinar, Dr Blier & Dr Cutler will be discussing the differences between normal anxiety & generalized anxiety disorder (GAD), the pharmacology treatments in GAD & also the challenges in managing GAD. Both experts will be sharing evidence based data and also their personal clinical experiences in this virtual event.
WATCH NOW
Pierre BlierCanada
Andrew J. CutlerUnited States
- All
- Psychiatry
- Neurology
-
LIVE
MDD MASTERCLASS 2023: From acute to maintenance phase in the management of MDD: How can patient perspectives help improve outcomes?
March 22 2022, Wednesday 1300 - 1430 or 1900 - 2030 CET
· Password: Masterclass2023During this upcoming Masterclass, global experts Professor Andrea Fagiolini, Dr Stavroula Bargiota, and Professor Gregor Hasler will come together virtually in a live interactive webinar. They will explore how patient perspectives can help improve the management of MDD and will consider common challenges faced by both patients and healthcare professionals in the acute and maintenance phases of MDD, including emotional blunting and anhedonia, and residual symptoms in MDD. Some of the most recent clinical research, including data on vortioxetine*, will be featured in these contexts. The faculty will also share and discuss their own clinical experiences and expert perspectives on common clinical challenges encountered during the acute and maintenance phases of MDD treatment. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.
REGISTER NOW
Andrea FagioliniItaly
Stavroula BargiotaGreece
Gregor HaslerSwitzerland -
LIVE
The Evolution of Pharmacological Treatment Options, and The Role Of A Multimodal-Acting Antidepressant
Apr 19 Wednesday 1930hr - 2030hr GMT+8
In this webinar, our experts will discuss the mechanism of action of different pharmacological options and evaluate their clinical effects. The experts will come together to share practical clinical insights of using different psychotropic medications. Appropriate use of medications based on the specific symptoms or patient populations will be presented as well. The webinar will also explore the dose-response relationship of antidepressant treatments in relation to efficacy and safety. Some of the most recent data on vortioxetine will be featured in this 60 minutes webinar.
REGISTER NOW
Andrea FagioliniItaly
Cyrus Ho Su HuiSingapore -
RECORDED
Treatment on Major Depressive Disorder with Neurological Diseases
Major depressive disorder (MDD) is often comorbid with neurological diseases such as post stroke, Alzheimer’s disease, Parkinson’s disease and contribute to the chronicity and severity of the disease. In this webinar, the role of antidepressants in managing MDD in these diseases will be presented by three experts in the field, as well as sharing of their practical experience in the decision making process on disease management via patient cases.
WATCH NOW
Pratap ChokkaCanada
Muzaffar SiddiquiCanada
John HarrisonUK -
RECORDED
TSAD WFH #9: Choosing the First Choice; MDD Symptoms & Subtypes
This Webinar is covers the topics as below: • Vortioxetine; a multimodal antidepressant • MDD and its heterogeneity • MDD symptoms and their specific treatments • MDD subtypes and their specific treatments
WATCH NOW
Paul ThisayakornThailand -
RECORDED
Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder
Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.
WATCH NOW
Roger S. McIntyreCanada
Gregory MattinglyUnited States -
RECORDED
Masterclass Webinar Series - Anhedonia and Emotional Blunting in Major Depressive Disorder - Addressing Challenges in clinical management of MDD
Anhedonia is an integral clinical feature of MDD (major depressive disorder) which is often neglected in clinical practice, defined by the lack of pleasure and motivation. Treatment with antidepressants could cause emotional blunting in some patients, which phenotypically overlaps with anhedonia. In this webinar, the challenges in clinical management of anhedonia and emotional blunting will be addressed, as well as the clinical approach and choice of optimal treatment options.
WATCH NOW
Roger S. McIntyreCanada
Andrea FagioliniItaly -
RECORDED
Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?
The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.
WATCH NOW
Andrea FagioliniItaly
Andrew J. CutlerUnited States -
RECORDED
Masterclass Webinar Series - Addressing functional challenges for patients with MDD
The definition of treatment success in MDD (major depressive disorder) has evolved across the years to full functional recovery, where the patient returns back to a premorbid level of functioning. This requires the complete treatment of mood, cognitive and physical symptoms of MDD, and the choice of antidepressant is integral to full recovery. In this webinar, the speakers will address the challenges to achieving functional recovery for MDD patients, and present clinical evidence for vortioxetine as a treatment option, as well as share their practical experience.
WATCH NOW
Pratap ChokkaCanada
Iria GrandeSpain -
RECORDED
Treatment Challenges in Managing GAD
In this webinar, Dr Blier & Dr Cutler will be discussing the differences between normal anxiety & generalized anxiety disorder (GAD), the pharmacology treatments in GAD & also the challenges in managing GAD. Both experts will be sharing evidence based data and also their personal clinical experiences in this virtual event.
WATCH NOW
Pierre BlierCanada
Andrew J. CutlerUnited States -
RECORDED
The art of disclosing depression to your patients - Focus on depression in younger adults
Do you struggle with disclosing mental disorders such as major depressive disorder (MDD) to your patients? How much do bedside manners really matter to the treatment plan? This session will discuss the trending topic of establishing the patient-doctor alliance and effective communication. In addition, the changing landscape of the treatment goal and management of MDD will be discussed, as well as practical advice via case studies of MDD management in active adults.
WATCH NOW
Pratap ChokkaCanada
Roger S. McIntyreCanada -
RECORDED
The art of disclosing depression to your patients - Focus on depression in older population
Major depressive disorder (MDD) in the elderly is often accompanied with other chronic comorbidities. The treatment plan is hence complicated by polypharmacy with potential drug-drug interactions, which is further compounded by changing pharmacokinetics as we age. This session will delve into the management of MDD in elderly patients, with these important considerations in mind. The speakers will also discuss prescribing practicalities in the form of case studies in this population.
WATCH NOW
Pratap ChokkaCanada
Roger S. McIntyreCanada
